神经元来源外泌体评估艾塞那肽对帕金森病运动功能分子机制的作用
该研究为Exenatide-PD试验的二次分析,从60例中度帕金森病患者血清中提取神经元来源外泌体,评估艾塞那肽对脑胰岛素/Akt信号通路的影响。结果显示艾塞那肽组48周和60周时胰岛素受体底物1酪氨酸磷酸化显著增加,且下游Akt和mTOR表达升高,mTOR水平与运动评分改善相关。提示外泌体生物标志物可用于监测靶点 engagement。
要点
- 艾塞那肽可增强帕金森病患者神经元外泌体中胰岛素受体底物1的酪氨酸磷酸化。
- 艾塞那肽组下游Akt和磷酸化mTOR表达升高,且mTOR水平与UPDRS part 3 off-medication评分改善相关。
- 神经元来源外泌体可作为临床试验中药物靶点 engagement 的客观生物标志物。
核心结论
- 艾塞那肽 engages 脑胰岛素、Akt和mTOR信号通路,为Exenatide-PD试验的临床发现提供机制背景。
- 基于外泌体的生物标志物有潜力作为靶向神经元通路药物的靶点 engagement 的客观指标。
研究设计与样本
- 研究为单中心Exenatide-PD试验的二次分析,纳入60例中度帕金森病患者,随机接受每周2 mg艾塞那肽或安慰剂治疗48周,随后12周洗脱期。
- 从血清中提取细胞外囊泡(包括外泌体),通过抗L1细胞黏附分子抗体富集神经元来源,用电化学发光法检测目标蛋白。
临床怎么用
- 在帕金森病临床试验中,可考虑采用神经元来源外泌体检测胰岛素/Akt/mTOR通路标志物以评估药物靶点 engagement。
- 艾塞那肽对脑胰岛素信号通路的增强作用为解释其运动功能获益提供了机制依据。
局限性
- 研究为单中心试验的二次分析,样本量有限(艾塞那肽组31例,安慰剂组29例,排除1例数据)。
- 外泌体提取与检测方法未在摘要中详述,可能影响结果的可推广性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Exenatide, a glucagon-like peptide 1 agonist used in type 2 diabetes, was recently found to have beneficial effects on motor function in a randomized, placebo-controlled trial in Parkinson disease (PD). Accumulating evidence suggests that impaired brain insulin and protein kinase B (Akt) signaling play a role in PD pathogenesis; however, exploring the extent to which drugs engage with putative mechnisms in vivo remains a challenge. OBJECTIVE: To assess whether participants in the Exenatide-PD trial have augmented activity in brain insulin and Akt signaling pathways. DESIGN, SETTING, AND PARTICIPANTS: Serum samples were collected from 60 participants in the single-center Exenatide-PD trial (June 18, 2014, to June 16, 2016), which compared patients with moderate PD randomized to 2 mg of exenatide once weekly or placebo for 48 weeks followed by a 12-week washout period. Serum extracellular vesicles, including exosomes, were extracted, precipitated, and enriched for neuronal source by anti-L1 cell adhesion molecule antibody absorption, and proteins of interest were evaluated using electrochemiluminescence assays. Statistical analysis was performed from May 1, 2017, to August 31, 2017. MAIN OUTCOMES AND MEASURES: The main outcome was augmented brain insulin signaling that manifested as a change in tyrosine phosphorylated insulin receptor substrate 1 within neuronal extracellular vesicles at the end of 48 weeks of exenatide treatment. Additional outcome measures were changes in other insulin receptor substrate proteins and effects on protein expression in the Akt and mitogen-activated protein kinase pathways. RESULTS: Sixty patients (mean [SD] age, 59.9 [8.4] years; 43 [72%] male) participated in the study: 31 in the exenatide group and 29 in the placebo group (data from 1 patient in the exenatide group were excluded). Patients treated with exenatide had augmented tyrosine phosphorylation of insulin receptor substrate 1 at 48 weeks (0.27 absorbance units [AU]; 95% CI, 0.09-0.44 AU; P = .003) and 60 weeks (0.23 AU; 95% CI, 0.05-0.41 AU; P = .01) compared with patients receiving placebo. Exenatide-treated patients had elevated expression of downstream substrates, including total Akt (0.35 U/mL; 95% CI, 0.16-0.53 U/mL; P < .001) and phosphorylated mechanistic target of rapamycin (mTOR) (0.22 AU; 95% CI, 0.04-0.40 AU; P = .02). Improvements in Movement Disorders Society Unified Parkinson's Disease Rating Scale part 3 off-medication scores were associated with levels of total mTOR (F4,50 = 5.343, P = .001) and phosphorylated mTOR (F4,50 = 4.384, P = .04). CONCLUSIONS AND RELEVANCE: The results of this study are consistent with target engagement of brain insulin, Akt, and mTOR signaling pathways by exenatide and provide a mechanistic context for the clinical findings of the Exenatide-PD trial. This study suggests the potential of using exosome-based biomarkers as objective measures of target engagement in clinical trials using drugs that target neuronal pathways.
引用
- Athauda D, Gulyani S, Karnati HK, et al. Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. JAMA Neurol. 2019. PMID: 30640362. doi:10.1001/jamaneurol.2018.4304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。